Safety and tolerability of 13-valent pneumococcal conjugate vaccine in the elderly: An observational study in Liguria Region, Italy

BACKGROUND: In September 2011 the European Medical Agency authorized the use of 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥50 years. The same occurred in the US in December 2011 when the Food and Drug Administration approved the use of PCV13 in the same target age-group with in...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Hum Vaccin Immunother
Autori principali: Durando, Paolo, Rosselli, Roberto, Cremonesi, Ilaria, Orsi, Andrea, Albanese, Erika, Barberis, Ilaria, Paganino, Chiara, Trucchi, Cecilia, Martini, Mariano, Marensi, Lorenzo, Turello, Valter, Study Group, the Ligurian Pneumococcal, Bregante, Alessandro, Cacciani, Roberto, Iudici, Rocco, La Marca, Diego, Pedano, Leonardo, Petrucci, Amadio Franco, Santolini, Maria, Sbisà, Valentina, Zacconi, Monica
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2014
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4514209/
https://ncbi.nlm.nih.gov/pubmed/25483531
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/hv.34420
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi